Table 4. Pgp Upregulation Ex Vivo Before... | American Society of Hematology

Table 4.

Pgp Upregulation Ex Vivo Before Treatment Correlated With the Subsequent Pgp Changes In Vivo After Chemotherapy

Patient Diagnosis (patient no.)	Ex Vivo				In Vivo
	Pgp Status^4-150				In Vivo
	No Drug	IDA	MX2	EPI^4-151	Actual Treatment (drugs)	Response^‡ to Treatment	Pgp Status on Subsequent Presentation (time after initial chemotherapy)^4-150
AML (1)	1.0	1.23	1.34	1.23	IDA/AraC	Refractory	1.76 (3 mo)
BT-CML (7)	0.75	1.50	2.46	2.61	Hydroxyurea	Refractory	1.19 (1 mo)
BT-CML (8)	0.87	2.20	2.30	3.27	Hydroxyurea/AraC	Refractory	1.51 (5 mo)

Patient Diagnosis (patient no.)	Ex Vivo				In Vivo
	Pgp Status^4-150				In Vivo
	No Drug	IDA	MX2	EPI^4-151	Actual Treatment (drugs)	Response^‡ to Treatment	Pgp Status on Subsequent Presentation (time after initial chemotherapy)^4-150
AML (1)	1.0	1.23	1.34	1.23	IDA/AraC	Refractory	1.76 (3 mo)
BT-CML (7)	0.75	1.50	2.46	2.61	Hydroxyurea	Refractory	1.19 (1 mo)
BT-CML (8)	0.87	2.20	2.30	3.27	Hydroxyurea/AraC	Refractory	1.51 (5 mo)

F4-150

Pgp status was expressed as the ratio of the arithmetic mean of fluorescence (MCF) of MRK 16-labeled cells versus IGg_2a-labeled controls.

F4-151

Blasts were treated with 20 ng/mL IDA, 50 ng/mL MX2, or 100 ng/mL EPI for 16 hours before being subjected to Pgp analysis as described in Materials and Methods.

‡

All 3 patients died as a result of disease progression.

View Large

This Feature Is Available To Subscribers Only